DE60127571D1 - Tiagabine zur behandlung von diabetischer neuropathie - Google Patents

Tiagabine zur behandlung von diabetischer neuropathie

Info

Publication number
DE60127571D1
DE60127571D1 DE60127571T DE60127571T DE60127571D1 DE 60127571 D1 DE60127571 D1 DE 60127571D1 DE 60127571 T DE60127571 T DE 60127571T DE 60127571 T DE60127571 T DE 60127571T DE 60127571 D1 DE60127571 D1 DE 60127571D1
Authority
DE
Germany
Prior art keywords
diabetic neuropathy
tiagabine
treatment
migraine
butenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60127571T
Other languages
English (en)
Other versions
DE60127571T2 (de
Inventor
Stephen D Collins
Roger L Deaton
William J Giardina
Adrienne L Gilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE60127571D1 publication Critical patent/DE60127571D1/de
Publication of DE60127571T2 publication Critical patent/DE60127571T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE60127571T 2000-10-20 2001-10-19 Tiagabine zur behandlung von diabetischer neuropathie Expired - Lifetime DE60127571T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69336100A 2000-10-20 2000-10-20
US693361 2000-10-20
PCT/US2001/051407 WO2002038144A2 (en) 2000-10-20 2001-10-19 The use of tiagabine for treatment of diabetic neuropathy and migraine

Publications (2)

Publication Number Publication Date
DE60127571D1 true DE60127571D1 (de) 2007-05-10
DE60127571T2 DE60127571T2 (de) 2008-01-24

Family

ID=24784340

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127571T Expired - Lifetime DE60127571T2 (de) 2000-10-20 2001-10-19 Tiagabine zur behandlung von diabetischer neuropathie

Country Status (8)

Country Link
EP (1) EP1331933B1 (de)
JP (1) JP4387102B2 (de)
AT (1) ATE357916T1 (de)
CA (1) CA2421042C (de)
DE (1) DE60127571T2 (de)
ES (1) ES2284711T3 (de)
MX (1) MXPA03003310A (de)
WO (1) WO2002038144A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583562B1 (de) 2003-01-06 2011-06-15 Angiochem Inc. Angiopep-1, verwandte verbindungen, und deren verwnedungen
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis

Also Published As

Publication number Publication date
EP1331933A2 (de) 2003-08-06
DE60127571T2 (de) 2008-01-24
JP4387102B2 (ja) 2009-12-16
ATE357916T1 (de) 2007-04-15
MXPA03003310A (es) 2003-09-10
EP1331933B1 (de) 2007-03-28
ES2284711T3 (es) 2007-11-16
WO2002038144A8 (en) 2002-07-11
CA2421042C (en) 2011-07-05
CA2421042A1 (en) 2002-05-16
WO2002038144A2 (en) 2002-05-16
JP2004513145A (ja) 2004-04-30

Similar Documents

Publication Publication Date Title
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE69905938D1 (de) Kombination von duloxetin mit nichtsteroid-entzündungshemmern für die behandlung von schmerz
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
NO20060416L (no) Ny anvendelse I
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
BR0008958A (pt) Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE323693T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
ES2119094T3 (es) Inhibicion de la hemorragia uterina disfuncional.
NO20005668L (no) Forbindelser med veksthormonfrigjörende egenskaper
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
DE60127571D1 (de) Tiagabine zur behandlung von diabetischer neuropathie
DE69808475T2 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
DE60015098D1 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose
SE0301883D0 (sv) New use II
SE0301885D0 (sv) New use IV
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition